Early Phase 1 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older, of any gender
• People who have a confirmed diagnosis of hepatocellular carcinoma (liver cancer), confirmed using recognised medical guidelines
• People whose liver cancer cannot be removed by surgery
• People whose liver cancer has gotten worse after at least one standard treatment, or who were not suitable for standard treatments, or who are unlikely to benefit from them
• People who have at least one measurable area of cancer that can be tracked using a specific imaging method (called mRECIST)
• People with a life expectancy of at least 12 weeks
• People whose general physical functioning falls within a certain range on a standard medical scale (called ECOG Performance Status 0 to 2), meaning they are able to carry out at least some daily activities (confirm with trial site)
• Men who are able to father children, and women who could become pregnant, who are willing to use a highly effective form of contraception throughout the trial and for 6 months after the trial treatment ends
• Women of childbearing age who have had a negative blood pregnancy test within 7 days before starting the trial treatment
• People who are willing to give written consent to participate and are able to follow the trial requirements

Who may not be able to join:

• People whose liver is not working well enough, based on specific blood test results measuring liver proteins and enzymes (confirm with trial site for exact levels)
• People whose kidneys are not working well enough, based on specific blood test results (confirm with trial site for exact levels)
• People with low levels of certain blood cells (white blood cells, platelets, or red blood cells), below specific levels measured by blood tests (confirm with trial site)
• People with a blood clotting measure (called INR) above a certain level, indicating a blood clotting problem
• People who have previously had a liver transplant
• People with poorly controlled high blood pressure, diabetes, or serious heart or lung conditions
• People whose cancer has spread outside the liver and who have not yet tried a first-line (initial standard) systemic treatment, unless they were not suitable for such treatment — or people who are currently responding well to systemic treatment
• People who have received certain cancer treatments (such as targeted therapy, immunotherapy, chemotherapy, or radiation) within a recent window of time before the trial starts (ranging from 2 to 4 weeks depending on the treatment type), unless the cancer continued to progress despite those treatments
• People who are still experiencing side effects of grade 2 or higher from previous cancer treatments (except for hair loss or other effects judged manageable by the medical team)
• People who have had serious liver-related complications — such as gastrointestinal bleeding, significant confusion caused by liver disease, or fluid build-up in the abdomen that is difficult to treat — within 2 weeks before starting the trial
• People with an active, uncontrolled infection (such as a lung or abdominal infection)
• People who have had another type of cancer within the past 5 years, with some exceptions for certain low-risk cancers that were treated successfully (confirm with trial site)
• People with certain levels of hepatitis B or hepatitis C virus still active in their blood, above specific thresholds (confirm with trial site)
• People who are HIV-positive
• People who are allergic to MRI contrast dye (the substance used to enhance MRI scans)
• Women who are pregnant, breastfeeding, or may be pregnant
• People who have taken part in another clinical drug trial within 4 weeks before starting this trial
• People who have any other medical condition that the trial doctor believes would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.